Fortune 1000 brands. Seven-figure contracts.

The most important number in Eli Lilly’s third-quarter report this morning has nothing to do with Mounjaro or Zepbound. It is the sales line for Foundayo, the oral obesity pill that Lilly launched in April and that could, over time, reshape weight-loss medicine from an injection business into something a patient picks up at a CVS without a sharps container.

Analysts expect Lilly to post earnings of $5.68 per share on revenue of $22.58 billion. In the same quarter a year earlier, the company reported $7.02 per share on revenue of $17.60 billion. The EPS decline looks alarming in isolation; it reflects the weight of acquired in-process R&D charges that have run through reported earnings all year, not a deteriorating business. The revenue trajectory is what matters, and that would mark growth of roughly 28% from a year earlier.

Investors are likely to watch sales of Mounjaro, which analysts project at about $10.04 billion, and Zepbound, expected to contribute roughly $5.03 billion. Together the two drugs are projected at about $15.07 billion, or roughly two-thirds of expected revenue. Those numbers will come in around where analysts expect, or they will not. Either way, the more interesting question sits elsewhere.

Lilly’s newly launched once-daily oral GLP-1 pill, Foundayo, generated $98 million in second-quarter sales following its April launch. That was a modest start for a drug that had entered a market Novo Nordisk had gotten a jump on in December 2025, when the Danish company won FDA approval for oral Wegovy, a once-daily 25 mg tablet indicated for chronic weight management. Novo launched the pill in January 2026, giving it a first-to-market advantage.

Lilly’s counter-argument is convenience. Lilly touts Foundayo’s flexibility: it can be taken any time of day without restrictions on food and water, whereas oral Wegovy must be swallowed first thing in the morning on an empty stomach, 30 minutes before anything else. That distinction matters more than it sounds. Adherence in chronic disease is almost always a compliance story, and removing a daily behavioral requirement tends to move prescription volume.

The marketing push was supposed to accelerate in Q3. Lilly activated its in-person Foundayo sales force on April 17, with plans to kick off the broader promotional push in 2026’s third quarter. This morning’s report is the first reading on whether that push is landing. Lilly has said Foundayo captured more than 30% of new U.S. patients starting oral weight-loss medicines. The absolute dollar figure will tell investors whether share is converting to revenue at a rate that justifies the spend.

The oral GLP-1 field is not standing still while Lilly and Novo trade market share. Viking Therapeutics has launched a Phase 3 program for its own once-daily oral obesity pill, raising the acquisition price for any deal Lilly might pursue.

The advertising war intensifies the stakes. Novo Nordisk lost a bid in a U.S. court earlier this week to temporarily block Lilly from running advertisements that claim its drugs are more powerful, with U.S. District Judge Zahid Quraishi ruling Monday that Lilly can continue to make the disputed claims while Novo proceeds with its lawsuit. One commercial included a voiceover claim that people using Zepbound on average lost 50 pounds while people using Wegovy on average lost 33 pounds. Those ads remain on air. Whether they are accelerating Foundayo scripts alongside injectable Zepbound and Mounjaro is a question today’s report begins to answer.

Both companies seek to boost their share of a global market for obesity treatments that Bloomberg Intelligence has estimated could reach about $120 billion a year by 2030. The injectable race is largely settled: Zepbound has become a leading choice among doctors, and multiple surveys and pharmacy-benefit snapshots have suggested it is taking share from Wegovy. The oral race is only months old and genuinely open.

A disciplined long-term investor should treat today’s Foundayo number as a data point, not a verdict. Foundayo could prove to be a commercial game-changer for Lilly, but near-term and peak-sales forecasts vary widely across analysts and will ultimately depend on access, adherence, and how quickly the pill category expands. Getting from here to there requires winning a pill market that Novo currently leads, in a category where brand loyalty is building fast. The number that posts this morning tells us how that race looked through September. The harder question is whether Lilly’s oral advantage in convenience compounds over time the way its injectable advantage in efficacy already has.